Recombinant Human IL12B Protein，His

Interleukin-12 beta (IL-12B) is a crucial component of the interleukin-12 (IL-12) cytokine family, playing a vital role in the immune response by regulating T-cell and natural killer (NK) cell activity. It is composed of two subunits, IL-12A and IL-12B, with the latter being essential for the biological activity of the IL-12 heterodimer. Research into IL12B recombinant protein has gained significant attention due to its potential therapeutic applications in various diseases, including cancer, autoimmune disorders, and infectious diseases. The ability of IL-12 to enhance the production of interferon-gamma (IFN-γ) and promote Th1 polarization positions it as a promising agent for immunotherapy. Recombinant IL12B can be utilized not only as a therapeutic protein but also as a research tool to study immune mechanisms and the modulation of host responses to pathogens. The development of recombinant IL12B protocols has opened avenues for investigating its effects on T-cell differentiation and its ability to elicit robust immune responses. Furthermore, studies on polymorphisms in the IL12B gene have highlighted its role in susceptibility to diseases, making it a target for precision medicine approaches. As a result, understanding the structure, function, and regulatory mechanisms of IL12B holds significant potential for developing new strategies to manipulate the immune system for therapeutic benefits. Overall, IL12B recombinant protein research is pivotal in elucidating immune pathways and laying the groundwork for innovative treatments in immunology and oncology.